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Gastric malignancy is associated with high mor-
bidity rates and poor prognoses, and accounts for
almost 10% of new cancers worldwide.1 In some
countries, especially those in Far East Asia such
as China, Japan and Korea, this disease is one 
of the leading causes of cancer-related deaths.2
Although the global incidence is declining, gas-
tric cancer still affects public health substantially
and results in the growth of an already considerable
economic burden.1,2
To help prevent gastric cancer, numerous 
investigators have sought to identify risk factors
associated with gastric cancer, to build mathe-
matical models for predicting the efficacy of in-
tervention, and to test the precision of models in
clinical trials.3 Most studies have been based on
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the fact that Helicobacter pylori is one of the major
causes of gastric cancer.
H. pylori Infection and Risk of 
Gastric Cancer
H. pylori is a Gram-negative bacterium that se-
lectively colonizes the gastric mucosa. Infection
rates vary, with a mean of 20–40% in developed
countries and 60–80% in developing countries.4
After infection, the bacterium persists for the life-
time of the host. Prolonged infection may lead
to chronic gastritis, peptic ulcer, gastric cancer,
and/or mucosa-associated lymphoid tissue (MALT)
lymphoma.1
On the basis of epidemiologic studies, the
World Health Organization classified H. pylori as
a class I (definite) carcinogen in humans in 1994.4
Several meta-analyses have shown a strong and
consistent association between H. pylori infec-
tion and noncardiac gastric cancer (Table 1).5–8
An updated consensus has indicated that chronic
atrophic gastritis caused by H. pylori is the major
precursor of gastric cancer.9 In a recent study, the
attribution fraction of noncardiac gastric cancer
was 74% in developed countries and 78% in de-
veloping countries. These percentages represented
592,000 cases, or 5.5% of all cancers.10
In addition to epidemiologic observations,
data from animal studies have solidified the
causal relationship between H. pylori infection
and gastric cancer.11 Furthermore, biological stud-
ies have clarified the underlying molecular mech-
anisms.12–15 To sum up, epidemiologic, animal
and biological studies have provided consistent
evidence to confirm the role of H. pylori infection
in gastric carcinogenesis.16
Health Economic Models to Estimate 
the Efficacy of H. pylori Eradication
The strong link between H. pylori infection 
and gastric cancer presents a unique opportunity
for clinicians to actively intervene to improve
public health. One approach is to test asympto-
matic carriers of H. pylori and offer eradication
therapy before irreversible changes occur. Such
population-based intervention may theoretically
eliminate gastric cancer. However, the problems
of large samples, long-term follow-up, and ethi-
cal issues hinder the performance of randomized
controlled trials to measure outcomes such as
changes in the incidence of gastric cancer.17 A good
alternative to predict the late benefits of H. pylori
eradication is cost-effectiveness analysis with com-
puter simulation. This method allows researchers
to calculate the incremental cost-effectiveness ra-
tio, or the ratio of change in cost to change in 
effects, without the aforementioned limitations
(Table 2).18–24
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Table 1. Meta-analyses of the association between Helicobacter pylori infection and the risk of gastric cancer
Investigators Years Studies Summary OR (95% CI) Sources of heterogeneity
Huang et al5 1990–1996 5 cohort, 1.92 (1.32–2.78) Early or advanced gastric cancer, cardiac or 
14 case control noncardiac gastric cancer, population- or 
hospital-based control subjects, patient age
Eslick et al6 1983–1999 8 cohort, 2.04 (1.69–2.45) Patient age, intestinal- or diffuse-type 
34 case control gastric cancer
Xue et al7 1995–1998 11 case control* 3.00 (2.42–3.72) Not available
Wang et al8 1980–2006 19 case control 3.38 (2.15–5.33)† Early or advanced gastric cancer, sample size,
differentiated- or undifferentiated-type early 
gastric cancer
*Only studies in China were included; †OR expresses the prevalence of H. pylori infection in the comparison between patients with early gastric cancer and
control subjects without non-neoplasm. OR = odds ratio; CI = confidence interval.
Most cost-effectiveness analyses have focused
on populations with a low prevalence of H. pylori
and a low risk for gastric cancer.18–22 Parsonnet
et al18 estimated the benefit of a test-and-treat
strategy in the United States. Assuming 30% risk
reduction in gastric cancer with eradication, they
found that the benefit would be optimized if
chemoprevention were implemented in patients
aged 50–70 years and if it targeted high-risk pop-
ulations (e.g. Japanese Americans). Fendrick et al19
evaluated testing, treating, retesting, and/or re-
treating H. pylori infection in the United States.
Testing and treating at an initial age of 40 years
was most cost-effective, although the incremental
cost-effectiveness ratio of retesting and/or retreating
remained acceptable. Knowing that H. pylori that
expresses cagA protein increases the risk of gastric
cancer threefold, Harris et al20 analyzed testing
and treating in the United States. Screening for
cagA-positive strains alone did not improve cost-
effectiveness compared with screening for all H.
pylori strains.
In a randomized trial, Mason et al21 evaluated
the economic impact of a test-and-treat approach
for H. pylori infection in the United Kingdom. The
program would have been cost-effective even if the
mortality rate were reduced by only 10%. Roderick
et al22 also confirmed the cost-effectiveness of
population screening for H. pylori in the United
Kingdom. However, the benefit was sensitive to
the efficacy of eradication on lowering the inci-
dence of gastric cancer, to the risk associated with
complicated peptic ulcers, and to the effect of
opportunistic testing in patients with dyspepsia.
These factors indicated substantial uncertainty.
In areas in which gastric cancer is highly preva-
lent, traditional screening is based on secondary
prevention (e.g. testing and endoscopy). For in-
stance, photofluorography and measurement of
serum pepsinogen concentrations can help to
identify high-risk individuals and to refer them for
confirmatory endoscopy.25 Wang et al23 suggested
that testing and treating of H. pylori infection was
feasible in China if eradication could prevent 50%
of gastric cancers. In Taiwan, we previously in-
corporated the results of local preventive programs
and compared testing and treating for H. pylori
infection with traditional testing and endoscopy.24
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Table 2. Health economic models to predict the efficacy of Helicobacter pylori eradication to prevent gastric cancer
ICER for strategy Optimal
Investigators Location Study design Strategy 2 vs.1 (cost/yr age for
of life saved)* screening (yr)
Parsonnet et al, 199618 US Literature review (1) No screen, (2) test and treat US$25,000 50–70
Fendrick et al, 199919 US Literature review (1) No screen, (2) test and treat, or US$6264 40
(3) test, treat, retest, and/or retreat
Harris et al, 199920 US, Literature review (1) No screen, (2) test and treat for US$25,100 50 
abroad all H. pylori strains, or (3) test and  
treat only for cagA+ strains
Mason et al, 200221 UK Randomized (1) No screen, (2) test and treat £14,200 40–49 
controlled 
trial (n = 2329)
Roderick et al, 200322 UK Literature review (1) Opportunistic H. pylori treatment, £5860 40
(2) test and treat 
Wang et al, 200323 China Literature review (1) No screen, (2) test and treat ¥1374 30–40
Lee et al, 200724 Taiwan Prospective (1) No screen, (2) test and treat, US$17,044 30
uncontrolled (3) pepsinogen test and 
trial (n = 1654) endoscopic confirmation
*In all studies, strategy 2 was the strategy of choice. ICER = incremental cost-effectiveness ratio.
Given a reduction in the initial transition rate
(i.e. from normal mucosa to chronic active gas-
tritis), our results suggest that eradication of 
H. pylori early in life can substantially reduce the
risk of mortality and improve cost-effectiveness.
Clinical Trials of H. pylori Eradication to
Prevent Gastric Cancer
Population-specific characteristics can confound
the cost-effectiveness of H. pylori eradication.
Therefore, the applicability of models should be
confirmed in local clinical trials. The chemopre-
vention trials reported to date can be categorized
according to differences in their target popula-
tions and outcome measures (Table 3).26–42 Areas
with high incidences of gastric cancer are East
Asia and the Andean regions of South America,
whereas North America, Northern Europe, Africa
and Southeast Asia have relatively low rates.1 It is
reasonable that most population-based chemo-
prevention trials have been conducted in devel-
oping countries to increase the statistical power
for detecting benefits of H. pylori eradication.
One limitation is that most of the data sup-
porting the efficacy of H. pylori eradication have
been based on surrogate outcomes of histologic
regression. If one considers the endpoint of a 
reduction in gastric cancer, only one random-
ized trial, conducted in China, has demonstrated
risk reduction; the change was 37% after 7.5
years.41 Although this result was not statistically
significant, subgroup analysis showed a substan-
tial reduction in the incidence of gastric cancer
for subjects without premalignant changes (e.g.
atrophic gastritis, intestinal metaplasia, and 
dysplasia). The results suggested a point of no 
return in that the benefits of H. pylori eradica-
tion might diminish at an advanced stage, 
when many types of molecular damage become
irreversible.
For developed countries with a low risk of
gastric cancer, attention has focused on saving
costs related to managing dyspepsia.34–39 In a
mass screening program conducted in the United
Kingdom, Moayyedi et al34,35 and Ford et al36
found that dyspepsia-related expenditure declined
after H. pylori was eradicated and that the savings
were greater than the initial cost of a test-and-treat
strategy. In their randomized trial in the United
Kingdom, Lane et al38 confirmed that testing and
treating reduced the costs associated with dyspepsia
by 30% at 2 years after eradication.
H. pylori Infection and Changes in the
Modern Disease Spectrum
Among developed countries, the parallel epi-
demics of obesity and metabolic disorders have
suggested that the decline in H. pylori infections
might be an etiology.43 H. pylori infection is char-
acterized by chronic and persistent intragastric
inflammation, which may induce changes both
local to and remote from the primary site. Curing
H. pylori infection may attenuate local inflamma-
tion and, in turn, affect appetite and energy ex-
penditure.44–47 The remote effects of H. pylori
infection are related to a prominent immune 
response involving type 1 T-helper cells. This 
response may stimulate the secretion of insulin
counter-regulatory hormones and, therefore, con-
tribute to the pathogenesis of atherosclerosis and
colon neoplasms.48,49 Whether the decline in 
H. pylori infection can explain changes in mod-
ern disease entities deserves further observation,
especially in developing countries.
Major Scientific Challenge: Why Are
Some H. pylori-infected People More
Susceptible to Disease Than Others?
Although H. pylori has been identified as a major
cause of a wide range of gastrointestinal diseases,
only a few infected patients develop advanced
intragastric pathology, such as peptic ulcers (10–
15%) or gastric malignancies (1–3%).50 This ob-
servation points to a couple of major scientific
challenges: what mechanisms lead to cancer or
ulcer in susceptible carriers of H. pylori and vice
Y.C. Lee, et al
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versa; and, what mechanisms prevent pathologic
changes in other infected individuals?
Three main gastric phenotypes after H. pylori
infection are known. The first is mild pan-gastritis,
which involves no alteration in gastric physiology
and, therefore, no clinically significant disease.
The second is corpus-predominant gastritis, which
is associated with gastric atrophy, hypochlorhydria
and an increased risk of gastric cancer. The third
phenotype is antrum-predominant gastritis, which
is associated with high secretion of gastric acid
and an increased risk of duodenal ulcer disease.51
This disease paradigm suggests that intra-
gastric inflammatory responses are related to an
interaction between host genetic makeup and
bacterial virulence factors, one which determines
the final outcomes after H. pylori infection.52 Many
researchers have focused on the role of strain-
specific virulence factors for H. pylori-related dis-
ease, including cagA, vacA, iceA, babA, oipA and
sabA.14 At the same time, host genetic suscepti-
bility may determine interindividual variation in
the magnitude of cytokine responses and may
contribute to the diversity of clinical outcomes.
A series of pro- and anti-inflammatory cytokine
polymorphisms are considered crucial to these
outcomes. Potential candidate genes include those
encoding interleukin (IL)-1β, IL-8, IL-10, tumor
necrosis factor-4 and toll-like receptor 4.53 Despite
recent progress in identifying susceptible hosts,
in determining bacterial genotypes, and in eluci-
dating their association with advanced intragastric
pathology, a geographical difference exists, and no
conclusive data have been noted. Moreover, the
underlying molecular mechanisms remain unclear.
Further in-depth studies in this field are warranted.
Concerns About Implementation on the
Population Level
H. pylori eradication is the most practical means
of preventing gastric cancer and peptic ulcer.
However, some concerns must be addressed. First,
the efficacy of population-based intervention for
gastric cancer remains inconclusive in terms of
long-term outcomes. Second, such an approach
may be enormously costly and especially cumber-
some for widespread implementation in devel-
oping countries.54 Third, as with the treatment of
other infectious pathogens, induction of antimi-
crobial resistance is a critical issue.55 Asymptomatic
carriers of H. pylori are usually less receptive to
treatment than others are, and adverse effects can
seriously affect their drug compliance. Low com-
pliance not only wastes medical resources but
also potentially accelerates the emergence of drug-
resistant strains due to premature discontinua-
tion of treatment. Finally, the interest in H. pylori
infection has recently extended from its role in
the etiology of diseases of the stomach and duo-
denum to those of the esophagus.39,56 H. pylori
infection may increase, decrease, or have no effect
on gastric acid secretion, which depends on the
pattern of gastritis.57,58 For high-risk subjects with
atrophic gastritis, eradicating H. pylori infection
may restore gastric acid secretion and thus increase
the risk of gastroesophageal reflux, although the
evidence remains inconclusive.56
Whether active treatment of H. pylori will 
accelerate the clinical course of certain modern
diseases remains unknown. Given the stated lim-
itations, the identification of highly susceptible
persons is crucial to selective testing and treatment.
For example, El-Omar et al59 found that relatives
of gastric cancer patients have a higher prevalence
of gastric atrophy and hypochlorhydria. Similarly,
Sheu et al60 showed that relatives of gastric can-
cer patients have greater gastric cycloxygenase-2
expression and higher incidence of precancerous
lesions after H. pylori infection. Both studies
highlighted the increase in host susceptibility in
such subjects and, consequently, eradication of
H. pylori infection is recommended.61 Moreover,
in Taiwan, the high prevalence of virulent triple-
positive H. pylori infection (cagA-, vacAs1- and
babA2-positive)62 may further justify prophylac-
tic treatment. Second, subjects with precancerous
lesions also have a higher risk for gastric cancer
but the benefit of H. pylori eradication has not
been confirmed by randomized controlled trials.
The concept of “a point of no return”41,63 implies
Y.C. Lee, et al
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that screening for H. pylori infection may be more
beneficial 10–20 years before the take-off age for
gastric cancer.62 Nonetheless, some well-designed
studies have shown the reversibility of advanced
gastric lesions.30,64 Currently, novel biomarkers
for risk prediction, including genetic, epigenetic
and proteinomic factors, are under extensive 
investigation.65
Alternatives to Eradication: Vaccination
and Socioeconomic Improvement
From the viewpoint of preventive medicine, vac-
cine development is the best way to control an
infectious process. However, no vaccine against
H. pylori is currently available. In addition, stud-
ies concerning acquisition and re-infection rates
of H. pylori have varied greatly. Direct person-to-
person contact has been suggested as the primary
route of transmission in developed countries,
whereas fecal–oral exposure to contaminated water
is implicated in developing countries.66 Risk factors
for transmitting H. pylori include overcrowding,
poor hygiene and sharing of beds by siblings.67 As
socioeconomic conditions improve in developing
regions, declining incidence of H. pylori infection
can reasonably be expected to lower the incidence
of gastric cancer, similar to that which has hap-
pened in Western countries. Nevertheless, even if
such a downward trend were to happen, it may
take a long time to accomplish without active in-
tervention in areas of highly prevalent infection.
Discussion and Conclusion
The discovery of a previously unappreciated mi-
crobial basis for peptic ulcer and gastric malig-
nancy brings new challenges, namely, defining
the etiologic effect of H. pylori infection and de-
signing strategies for preventing these common
gastroduodenal disorders.68 Today, eradication of
H. pylori is considered as the first-line treatment
of peptic ulcer disease and MALT lymphoma. 
In 2005, the Nobel Prize for Medicine that was
awarded to Marshall and Warren was a formal
recognition of their discovery that many peptic
ulcers were due to an infectious condition that
can be cured with antibiotics.
Elucidation of the central role of H. pylori in
carcinogenesis has increased expectations in our
ability to prevent gastric cancer by eradication of
this bacterium. However, the effect of primary
prevention in patients with premalignant gastric
lesions and the long-term results of randomized
clinical trials are still inconclusive. There is a clear
need for studies with large numbers of patients,
long follow-up, and careful control of the types
of cancer and underlying gastric mucosal condi-
tions. The current evidence does not enable us to
accurately assess the benefits of universal testing
and treatment. However, it is sufficient for targeted
intervention, that is, identifying subjects who are
susceptible to H. pylori-related diseases. Active
screening of the general population in areas with
high incidence of gastric cancer appears logical
but is not yet evidence-based. The test-and-treat
approach should be validated in randomized con-
trolled trials and, thus, still has a long way to go.
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